Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score
Hobyung Chung(Kindai University), Takashi Matsunaga(Shiga University of Medical Science), Shunsuke Takahashi(Kanagawa Dental University), Yasunori Minami, Toyokazu Fukunaga, Kazuomi Ueshima(Kindai University), Tatsuo Inoue, Satoru Hagiwara(Kindai University Hospital), Yasuhiro Sakaguchi(Jikei University Kashiwa hospital), Masatoshi Kudo(Kindai University)
Cited by 50
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Development of a Prokaryotic Universal Primer for Simultaneous Analysis of Bacteria and Archaea Using Next-Generation Sequencing
|PLoS ONE|2014|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k